Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696
Category
Published on
Abstract
LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.
Journal
Journal of Organic Chemistry. Volume 85, 2020, 6844–6853
DOI
10.1021/acs.joc.0c00473
Type of publication
Peer-reviewed journal
Affiliations
- Suzhou Novartis Technical Development Co., Ltd.
- Novartis Pharmaceuticals (China) Suzhou Operations
- Novartis Pharma AG
Article Classification
Research Article
Classification Areas
- Intermediate